Back to Stakeholders
Canadian psychedelic biotech that sold its DMT Phase 1 clinical trial assets to Cybin in 2022. Following the sale, Entheon has operated as a near-shell company with minimal employees and no active drug development programme.
Quick Facts
- Type
- Public Biotech
- Ticker
- CSE: ENBI
- Website
- Visit